ADMA Biologics, Inc. (ADMA)

Price$7.90

Value ScoreC

Growth ScoreC

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-67.15%

Price vs S&P 500 (4W)-29.12%

VGM Score43.79

Market Capitalization$1.85B

P/E Ratio (Annual)12.59x

All Metrics

P/CF (Annual)36.70x

Book Value / Share (Quarterly)$1.68

P/TBV (Annual)9.11x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)49.04%

Cash Flow / Share (Quarterly)$0.46

Price vs S&P 500 (YTD)-67.18%

Gross Margin (TTM)61.27%

Net Profit Margin (TTM)32.43%

EPS (TTM)$0.68

10-Day Avg Trading Volume3.38M

EPS Excl Extra (TTM)$0.68

Revenue Growth (5Y)64.62%

EPS (Annual)$0.60

ROI (Annual)26.74%

Gross Margin (Annual)57.39%

Net Profit Margin (5Y Avg)-13.41%

Cash / Share (Quarterly)$0.59

P/E Basic Excl Extra (TTM)11.19x

Revenue Growth QoQ (YoY)-0.27%

P/E Normalized (Annual)12.59x

ROA (Last FY)23.54%

Revenue Growth TTM (YoY)10.99%

EBITD / Share (TTM)$0.87

ROE (5Y Avg)-5.51%

Operating Margin (TTM)41.48%

Cash Flow / Share (Annual)$0.12

P/B Ratio4.74x

P/B Ratio (Quarterly)5.36x

Net Income / Employee (Annual)$227,100

EV / Revenue (TTM)3.74x

Net Interest Coverage (TTM)35.86x

ROA (TTM)27.37%

EPS Growth QoQ (YoY)71.73%

EV / EBITDA (TTM)9.02x

EPS Incl Extra (Annual)$0.60

Current Ratio (Annual)6.71x

Quick Ratio (Quarterly)3.73x

3-Month Avg Trading Volume5.73M

52-Week Price Return-59.64%

EV / Free Cash Flow (Annual)69.38x

P/E Incl Extra (TTM)11.19x

Revenue / Employee (TTM)$788,000

Tangible BV / Share (Quarterly)$1.68

P/S Ratio (Annual)3.63x

Asset Turnover (Annual)0.82x

52-Week High$22.37

Operating Margin (5Y Avg)-6.93%

EPS Excl Extra (Annual)$0.60

CapEx CAGR (5Y)12.45%

Tangible BV CAGR (5Y)40.88%

26-Week Price Return-51.22%

Quick Ratio (Annual)3.63x

13-Week Price Return-47.43%

Total Debt / Equity (Annual)0.15x

Current Ratio (Quarterly)6.95x

Enterprise Value$1.91B

Revenue / Share Growth (5Y)33.56%

Asset Turnover (TTM)0.84x

Book Value / Share Growth (5Y)18.97%

Revenue / Employee (Annual)$788,500

Inventory Turnover (Annual)1.15x

Pretax Margin (Annual)35.80%

Cash / Share (Annual)$0.37

3-Month Return Std Dev78.26%

Gross Margin (5Y Avg)33.70%

Net Income / Employee (TTM)$255,600

ROE (Last FY)30.78%

Net Interest Coverage (Annual)35.86x

EPS Basic Excl Extra (Annual)$0.60

P/FCF (TTM)17.03x

Receivables Turnover (TTM)4.33x

EV / Free Cash Flow (TTM)17.74x

Total Debt / Equity (Quarterly)0.50x

EPS Incl Extra (TTM)$0.68

Receivables Turnover (Annual)4.90x

ROI (TTM)31.32%

P/S Ratio (TTM)3.63x

Pretax Margin (5Y Avg)-15.38%

Revenue / Share (Annual)$2.08

Tangible BV / Share (Annual)$2.00

Forward P/E9.96x

Price vs S&P 500 (52W)-87.84%

P/E Ratio (TTM)11.19x

EPS Growth TTM (YoY)-19.25%

Year-to-Date Return-56.25%

5-Day Price Return-3.16%

EPS Normalized (Annual)$0.60

ROA (5Y Avg)2.12%

Net Profit Margin (Annual)28.80%

Month-to-Date Return-22.15%

Cash Flow / Share (TTM)$-0.07

EBITD / Share (Annual)$0.77

Operating Margin (Annual)36.87%

LT Debt / Equity (Annual)0.15x

P/CF (TTM)14.41x

ROI (5Y Avg)2.07%

P/E Excl Extra (TTM)11.19x

LT Debt / Equity (Quarterly)0.50x

EPS Basic Excl Extra (TTM)$0.68

P/TBV (Quarterly)5.37x

P/B Ratio (Annual)9.09x

Inventory Turnover (TTM)1.00x

Pretax Margin (TTM)40.47%

Book Value / Share (Annual)$2.01

Price vs S&P 500 (13W)-57.18%

Beta0.76x

P/FCF (Annual)67.24x

Revenue / Share (TTM)$2.12

ROE (TTM)38.97%

52-Week Low$7.21

vGradeC

gGradeC

mGradeF

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.19est. 0.20

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.11

4.00

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
ADMAADMA Biologics, Inc.	C	C	F	$7.90
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

ADMA Biologics manufactures and markets plasma-derived immunoglobulin (IG) and intravenous immunoglobulin (IVIG) products for immunodeficient patients and those at risk for infectious diseases. The company operates through ADMA BioManufacturing, its primary revenue source, and Plasma Collection Centers, supplemented by laboratory and contract manufacturing services. It also sells plasma-derived intermediate fractions generated from its FDA-approved manufacturing process. The company derives substantially all revenue from the United States market.